BNTC Benitec Biopharma Inc.

Nasdaq benitec.com


$ 15.76 $ 0.32 (2.09 %)    

Tuesday, 04-Nov-2025 14:03:33 EST
QQQ $ 620.89 $ -2.36 (-0.38 %)
DIA $ 470.34 $ -0.03 (-0.01 %)
SPY $ 675.69 $ -0.45 (-0.07 %)
TLT $ 89.93 $ 0.15 (0.17 %)
GLD $ 362.24 $ -1.36 (-0.37 %)
$ 15.86
$ 15.21
$ 15.77 x 14
$ 15.82 x 100
$ 15.02 - $ 15.66
$ 9.10 - $ 17.15
409,215
na
416.33M
$ 1.09
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 09-22-2025 06-30-2025 10-K
2 05-14-2025 03-31-2025 10-Q
3 02-14-2025 12-31-2024 10-Q
4 11-14-2024 09-30-2024 10-Q
5 09-26-2024 06-30-2024 10-K
6 05-13-2024 03-31-2024 10-Q
7 02-13-2024 12-31-2023 10-Q
8 11-13-2023 09-30-2023 10-Q
9 09-21-2023 06-30-2023 10-K
10 05-15-2023 03-31-2023 10-Q
11 02-13-2023 12-31-2022 10-Q
12 11-10-2022 09-30-2022 10-Q
13 09-02-2022 06-30-2022 10-K
14 05-16-2022 03-31-2022 10-Q
15 02-14-2022 12-31-2021 10-Q
16 11-15-2021 09-30-2021 10-Q
17 09-20-2021 06-30-2021 10-K
18 05-12-2021 03-31-2021 10-Q
19 02-09-2021 12-31-2020 10-Q
20 11-13-2020 09-30-2020 10-Q
21 09-23-2020 06-30-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-benitec-biopharma-raises-price-target-to-35

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Benitec Biopharma (NASDAQ:BNTC) with a Buy and raises the price...

 citizens-maintains-market-outperform-on-benitec-biopharma-raises-price-target-to-22

Citizens analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and raises the price tar...

 benitec-biopharma-provides-interim-clinical-results-for-bb-301-phase-1b2a-clinical-trial-following-administration-of-bb-301-cohort-1-patients-showed-significant-sustained-improvements-across-multiple-clinical-measures

Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechn...

 jmp-securities-reiterates-market-outperform-on-benitec-biopharma-maintains-20-price-target

JMP Securities analyst Silvan Tuerkcan reiterates Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and maintains $20...

 benitec-biopharma-files-for-mixed-shelf-offering-of-up-to-200m

-SEC Filing

 correction-benitec-biopharma-q4-eps-042-misses-033-estimate

Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $...

 oppenheimer-maintains-outperform-on-benitec-biopharma-lowers-price-target-to-29

Oppenheimer analyst Andreas Argyrides maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and lowers the price targe...

 benitec-biopharma-receives-green-light-to-advance-bb-301-trial-after-safety-review-cohort-2-enrollment-set-for-q4-2025

-In April 2025 the Sixth and Final Subject of Cohort 1 was Safely Treated with the Low Dose of BB-301 in the Phase 1b/2a Clinic...

 hc-wainwright--co-reiterates-buy-on-benitec-biopharma-maintains-28-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Benitec Biopharma (NASDAQ:BNTC) with a Buy and maintains $28 p...

 jmp-securities-reiterates-market-outperform-on-benitec-biopharma-maintains-20-price-target

JMP Securities analyst Silvan Tuerkcan reiterates Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and maintains $20...

 benitec-biopharma-q3-eps-024-beats-035-estimate

Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0...

 jmp-securities-maintains-market-outperform-on-benitec-biopharma-raises-price-target-to-20

JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and raises the pri...

 hc-wainwright--co-reiterates-buy-on-benitec-biopharma-maintains-28-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Benitec Biopharma (NASDAQ:BNTC) with a Buy and maintains $28 p...

 citizens-capital-markets-reiterates-market-outperform-on-benitec-biopharma-maintains-18-price-target

Citizens Capital Markets analyst Silvan Tuerkcan reiterates Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and mai...

 hc-wainwright--co-reiterates-buy-on-benitec-biopharma-maintains-28-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Benitec Biopharma (NASDAQ:BNTC) with a Buy and maintains $28 p...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION